

Factsheet H1/2017



COMPANY PROFILE

Fresenius is a global health care group providing products and services for dialysis, hospitals and outpatient medical care. In addition, Fresenius focuses on hospital operations. We also manage projects and provide services for hospitals and other health care facilities. More than 260,000 employees have dedicated themselves to the service of health in over 100 countries worldwide.

FRESENIUS GROUP IN FIGURES (IFRS)

€ in millions	H1/2017	H1/2016	Change	FY/2016
Sales and Earnings				
Sales	16,894	14,218	19%	29,471
EBIT	2,393	1,987	20%	4,302
Net income ²	916	736	24%	1,560
Earnings per ord. share in € ²	1.65	1.35	22%	2.85
Balance sheet and cash flow				
Total assets	52,897		13%	46,697
Non-current assets	40,098		15%	34,953
Equity ³	21,020		1%	20,849
Equity ratio ³	39.7%		--	44.6%
Net debt/EBITDA ^{4,5}	3.00		--	3.09 ⁷
Investments ⁶	7,130	1,179	--	2,559
Operating cash flow	1,683	1,333	26%	3,585
Operating cash flow in % of sales	10.0%	9.4%	--	12.2%
Profitability				
EBIT margin	14.2%	14.0%	--	14.6%
Return on equity after taxes (ROE) ²	13.3%		--	12.3%
Return on operating assets (ROOA) ⁴	9.8%		--	10.0%
Return on invested capital (ROIC) ⁴	8.1%		--	8.5%
Employees	268,508		15%	232,873

¹ Before special items

² Net income attributable to shareholders of Fresenius SE & Co. KGaA; before special items

³ Including noncontrolling interest

⁴ Pro forma acquisitions; before special items


⁵ At LTM average exchange rates for both net debt and EBITDA

⁶ Investments in property, plant and equipment, and intangible assets, acquisitions

⁷ Pro forma Quirónsalud

GROUP STRUCTURE

The operating business comprises the four business segments Fresenius Medical Care, Fresenius Kabi, Fresenius Helios and Fresenius Vamed, all of which are legally independent entities managed by the operating parent company Fresenius SE & Co. KGaA.



¹ As of June 30, 2017


BUSINESS SEGMENTS (IFRS)

€ in millions		H1/2017	H1/2016	Change	FY/2016
	Sales	9,019	7,942	14%	16,570
	EBIT	1,235	1,068	16%	2,409
	Sales	3,202	2,946	9%	6,007
	EBIT ¹	622	582	7%	1,171
	Sales	4,256	2,912	46%	5,843
	EBIT	537	332	62%	683
	Sales	481	472	2%	1,160
	EBIT	17	16	6%	69


¹ Before special items

- ▶ **Fresenius Medical Care** is the world's largest integrated provider of products and services for individuals undergoing dialysis because of chronic kidney failure. As of June 30, 2017, Fresenius Medical Care was treating 315,305 patients in 3,690 dialysis clinics.
- ▶ **Fresenius Kabi** Fresenius Kabi offers intravenously administered generic drugs, clinical nutrition and infusion therapies for seriously and chronically ill patients in the hospital and outpatient environments. The company is also a leading supplier of medical devices and transfusion technology products.
- ▶ **Fresenius Helios** is Europe's leading private hospital operator. The company comprises HELIOS Kliniken in Germany and Quirónsalud in Spain. HELIOS Kliniken operates 112 hospitals, thereof 88 acute care clinics and 24 post-acute care clinics, and treats more than 5.2 million patients annually. Quirónsalud operates 44 hospitals, 44 outpatient centers and around 300 occupational risk prevention centers, and treats approximately 9.7 million patients per year.
- ▶ **Fresenius Vamed** manages projects and provides services for hospitals and other health care facilities worldwide. The portfolio ranges along the entire value chain: from project development, planning, and turnkey construction, via maintenance and technical management, to total operational management.

SALES BY REGION



SALES BY BUSINESS SEGMENT




FRESENIUS SHARE/ADR

	Share
Securities code no.	578 560
ISIN	DE0005785604
Ticker symbol	FRE
ADR CUSIP	35804M105
ADR Ticker symbol	FSNUY
Number of shares (June 30, 2017)	554,295,631
Market capitalization (June 30, 2017)	€41.6 billion

RELATIVE SHARE PRICE PERFORMANCE FRESENIUS SHARE VS. DAX



DEVELOPMENT SHARE DIVIDENDS IN €



This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius does not undertake any responsibility to update the forward-looking statements in this release.

Fresenius SE & Co. KGaA
Registered Office: Bad Homburg, Germany
Commercial Register: Amtsgericht Bad Homburg, HRB 11852
Chairman of the Supervisory Board: Dr. Gerd Krick


General Partner: Fresenius Management SE
Registered Office: Bad Homburg, Germany
Commercial Register: Amtsgericht Bad Homburg, HRB 11673
Management Board: Stephan Sturm (Chairman), Dr. Francesco De Meo, Rachel Empey, Dr. Jürgen Götz, Mats Henriksson, Rice Powell, Dr. Ernst Wastler
Chairman of the Supervisory Board: Dr. Gerd Krick

SHARE PERFORMANCE¹

1 month	-2%
1st quarter	+1%
1 year	+14%
3 years	+107%
5 years	+175%
10 years	+296%

¹ Effective date/closing price: June 30, 2017

FRESENIUS GROUP: FINANCING MIX



GROUP OUTLOOK 2017 (IFRS)

	Targets 2017
Sales, growth (in constant currency)	15% – 17%
Net income ¹ , growth (in constant currency)	19% – 21% ²

¹ Net income attributable to shareholders of Fresenius SE & Co. KGaA

² Before transaction costs of ~€50 million for the acquisitions of Akorn Inc. and Merck KGaA's biosimilars business; before expected expenditures for the further development of Merck KGaA's biosimilars business of ~€50 million (expected closing Q3/17)

For the outlook of the business segments please see the Investor News of August 1, 2017.

FINANCIAL CALENDAR

	Dates
Report on 3rd quarter 2017	November 2, 2017
Annual General Meeting, Frankfurt/Main	May 18, 2018

Please note that these dates could be subject to modifications.

CONTACT

Fresenius SE & Co. KGaA

Else-Kröner-Straße 1, 61352 Bad Homburg v. d. H.
e-mail: ir-fre@fresenius.com
Internet: www.fresenius.com

Markus Georgi

Senior Vice President Telephone: ++49 61 72 6 08-24 85
Investor Relations Telefax: ++49 61 72 6 08-24 88

Follow us on twitter and linkedin

